

TECHNICAL AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph comprising lines 19-21 on page 10 with the following substitute paragraph:

C1 --In another embodiment of the invention, the human *Mda-7* promoter comprises the nucleotide sequence shown in SEQ ID NO:1 from the thymidine (T) at position 1 ~~-2241~~ to the cytosine (C) at position 2240  $\theta$ .--

Please replace the paragraph comprising lines 22-24 on page 11 with the following substitute paragraph:

C2 --In another embodiment of the invention, the promoter nucleotide sequence is identical to the sequence from the thymidine (T) at position 1 ~~-2241~~ to the cytosine (C) at position 2240  $\theta$  of SEQ ID NO:1.--

Please replace the paragraph comprising lines 26-29 on page 11 with the following substitute paragraph:

C3 --In another embodiment of the invention, the promoter nucleotide sequence is a nucleotide sequence functionally equivalent to the identical to the *Mda-7* promoter sequence from position 1 ~~-2241~~ to position 2240  $\theta$  of SEQ ID NO:1.--

Please replace the paragraph comprising lines 29-33 on page 13 with the following substitute paragraph:

C4 --As used herein "*Mda-7* promoter" means the promoter having about 2240 ~~2241~~ base pairs (bp) derived from the 5' flanking region of the *Mda-7* gene as shown in Figure 6 beginning with (T) thymidine at nucleotide position 1 ~~-2241~~ and ending with (C) cytosine at nucleotide position 2240  $\theta$ . See SEQ ID NO:1 as follows.--

Please replace the paragraph comprising line 3 on page 14 with the following substitute

paragraph:

c5 --3' - (1 -2241)--

Please replace the paragraph comprising line 16 on page 15 with the following substitute paragraph:

c6 --ACCTTTACTT CTGAAATGAC TTCCACGGCT GGGACG (+2286 +45)

**TECHNICAL AMENDMENTS TO THE DRAWINGS:**

Please substitute the original version of Figure 6 with the replacement version of Figure 6 contained herein.